



Universiteit
Leiden
The Netherlands

Optimizing the sequence of metastatic castration-resistant prostate cancer treatment options

Badrising, S.K.

Citation

Badrising, S. K. (2021, June 15). *Optimizing the sequence of metastatic castration-resistant prostate cancer treatment options*. Retrieved from <https://hdl.handle.net/1887/3188563>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3188563>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <https://hdl.handle.net/1887/3188563> holds various files of this Leiden University dissertation.

Author: Badrising, S.K.

Title: Optimizing the sequence of metastatic castration-resistant prostate cancer treatment options

Issue Date: 2021-06-15

OPTIMIZING THE SEQUENCE OF METASTATIC CASTRATION- RESISTANT PROSTATE CANCER TREATMENT OPTIONS

Sushil Koewarsingh Badrising

ISBN: 978-94-6421-308-9

Cover title: 'Optimizing the sequence of metastatic castration resistant prostate cancer treatment options'

Cover illustration: Muhammad Rahmadyo Narendra

Design and Layout: Bregje Jaspers, ProefschriftOntwerp.nl

Printing: Ipsonkamp printing

Copyright © Sushil K. Badrising, 2021. All rights reserved. No part of this book may be reproduced, stored in retrieval system, or transmitted in any form or by any means, without prior permission of the author.

The research described in this thesis was performed at the Division of Medical Oncology of the Netherlands Cancer Institute, the Netherlands and was supported by a grant from Bayer BV.

OPTIMIZING THE SEQUENCE OF METASTATIC CASTRATION- RESISTANT PROSTATE CANCER TREATMENT OPTIONS

PROEFSCHRIFT

ter verkrijging van
de graad van doctor aan de Universiteit Leiden,
op gezag van rector magnificus prof.dr.ir. H. Bijl,
volgens besluit van het college voor promoties
te verdedigen op dinsdag 15 juni 2021
klokke 11.15 uur

door

Sushil Koewarsingh Badrising
geboren te Amsterdam
in 1982

Promotor:

Prof. dr. J.B.A.G. Haanen

Copromotor:

dr. A.M. Bergman (Nederlands Kanker Instituut)

Leden Promotiecommisie:

Prof. dr. A.J. Gelderblom

Prof. dr. L.F. de Geus-Oei

Prof. dr. E.M.A. Bleiker

Prof. dr. R.J.A. van Moorselaar (Amsterdam UMC)

Prof. dr. R. de Wit (Erasmus UMC)

dr. T. van der Hulle

“A mind all logic is like a knife all blade. It makes the hand bleed that uses it.”

- Rabindranath Tagore

For my grandparents: Soekhradj, Bhoedanie, Jan and Silvie

TABLE OF CONTENTS

Chapter 1	General introduction	9
Chapter 2	Clinical activity and tolerability of Enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and Abiraterone treatment <i>Cancer 2014</i>	23
Chapter 3	Prognostic parameters for response to Enzalutamide after docetaxel and Abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation <i>The prostate 2016</i>	41
Chapter 4	Enzalutamide as a Fourth-or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate <i>Oncology 2016</i>	61
Chapter 5	A Prospective Observational Registry Evaluating Clinical Outcomes of Radium-223 Treatment in a Non-study Population <i>International journal of Cancer 2020</i>	77
Chapter 6	Integrated Analysis of Pain, Health-Related Quality of Life and Analgesic use in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radium-223 <i>Accepted for publication</i>	97
Chapter 7	Summarizing discussion	129
Appendices	English summary	147
	Nederlandse samenvatting	151
	PhD Portfolio	155
	Publications	157
	Dankwoord	159
	Curriculum Vitae	163

